Topic: epidermal growth factor receptor (EGFR)
An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.
Because of the China COVID-19 epidemic, AstraZeneca pared its 2020 revenue forecast—and at a time when three key cancer meds missed their marks.
It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.
Adding Cyramza to Roche’s Tarceva stalled tumor progression by 19.4 months, a seven-month improvement over Tarceva alone.
AstraZeneca’s Tagrisso is already rolling in previously untreated, EGFR-mutated lung cancer, but gold-standard survival data won't hurt.
AZ already has a Tagrisso nod for patients with previously untreated, EGFR-mutated lung cancer. But it’s shoring up its case with clutch new data.
England’s cost watchdogs won’t get behind AZ blockbuster Tagrisso. But in a change of events, they’re instead backing a Pfizer challenger.
AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med.
Eli Lilly has new data that could help expand Cyramza’s lung cancer footprint, but a tough marketing battle awaits.
Big Pharma firms touted growth in China; Genentech sues ex-staffers and biosim company; Janssen licenses Yuhan's potential Tagrisso rival.